This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schiller, J. H. Articles by Johnson, D. H. Search for Related Content PubMed PubMed Citation Articles by Schiller, J. H. Articles by Johnson, D. H. Social Bookmarking                            What's this?

Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy

From the William S. Middleton Veterans Administration Hospital and University of Wisconsin, Madison; University of Wisconsin, Milwaukee, WI; Eastern Cooperative Oncology Group, Dana-Farber Cancer Institute, Boston, MA; University of Rochester Cancer Center, Rochester; Beth Israel Medical Center, New York; Albany Medical Center, Albany; State University of New York, Syracuse, NY; Evanston Hospital, Evanston, IL; University of Washington, Seattle, WA; Latter-Day Saints Hospital and University of Utah School of Medicine, Salt Lake City, UT; Mayo Clinic, Rochester, MN; and Vanderbilt University Medical School, Nashville, TN.

Address reprint requests to Joan H. Schiller, MD, University of Wisconsin, Department of Medicine, Medical Oncology Section, K4/666 Clinical Science Center, 600 Highland Ave, Madison, WI 53792; email jhschill{at}facstaff.wisc.edu

PURPOSE: To determine the prognostic and predictive significance of p53 and K-ras mutations in patients with completely resected non–small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: Patients were randomized preoperatively to receive adjuvant postoperative radiotherapy (Arm A) or radiotherapy plus concurrent chemotherapy (Arm B). p53 protein expression was studied by immunohistochemistry (IHC) and p53 mutations in exons 5 to 8 were evaluated by single-strand conformational analysis. K-ras mutations in codons 12, 13, and 61 were determined using engineered restriction fragment length polymorphisms.

RESULTS: Four hundred eighty-eight patients were entered onto E3590; 197 tumors were assessable for analysis. Neither presence nor absence of p53 mutations, p53 protein expression, or K-ras mutations correlated with survival or progression-free survival. There was a trend toward improved survival for patients with wildtype K-ras (median, 42 months) compared with survival of patients with mutant K-ras who were randomized to chemotherapy plus radiotherapy (median, 25 months; P = .09). Multivariate analysis revealed only age and tumor stage to be significant prognostic factors, although there was a trend bordering on statistical significance for K-ras (P = .066). Analysis of survival difference by p53 by single-stranded conformational polymorphism and IHC, interaction of p53 and K-ras, interaction of p53 and treatment arm, nodal station, extent of surgery, weight loss, and histology did not reach statistical significance.

CONCLUSION: p53 mutations and protein overexpression are not significant prognostic or predictive factors in resected stage II or IIIA NSCLC. K-ras mutations may be a weak prognostic marker. p53 or K-ras should not be routinely used in the clinical management of these patients.

The contents of this study are solely the responsibility of the authors and do not represent the official views of the National Cancer Institute.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. J. Riely, J. Marks, and W. Pao KRAS Mutations in Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 201 - 205. [Abstract] [Full Text] [PDF]

				B. Besse and T. Le Chevalier Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect? J. Clin. Oncol., November 1, 2008; 26(31): 5014 - 5017. [Full Text] [PDF]

				M.-S. Tsao, S. Aviel-Ronen, K. Ding, D. Lau, N. Liu, A. Sakurada, M. Whitehead, C.-Q. Zhu, R. Livingston, D. H. Johnson, et al. Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5240 - 5247. [Abstract] [Full Text] [PDF]

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]

				H. H. Nelson, M. Wilkojmen, C. J. Marsit, and K. T. Kelsey TP53 mutation, allelism and survival in non-small cell lung cancer Carcinogenesis, October 1, 2005; 26(10): 1770 - 1773. [Abstract] [Full Text] [PDF]

				D. A. Eberhard, B. E. Johnson, L. C. Amler, A. D. Goddard, S. L. Heldens, R. S. Herbst, W. L. Ince, P. A. Janne, T. Januario, D. H. Johnson, et al. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib J. Clin. Oncol., September 1, 2005; 23(25): 5900 - 5909. [Abstract] [Full Text] [PDF]

				L. Thomas, L. A. Doyle, and M. J. Edelman Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy Chest, July 1, 2005; 128(1): 370 - 381. [Abstract] [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				K. M.W. Pisters and T. Le Chevalier Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3270 - 3278. [Abstract] [Full Text] [PDF]

				G. R. Simon, S. Sharma, A. Cantor, P. Smith, and G. Bepler ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer Chest, March 1, 2005; 127(3): 978 - 983. [Abstract] [Full Text] [PDF]

				L.C. AMLER, A.D. GODDARD, and K.J. HILLAN Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 483 - 488. [Abstract] [PDF]

				K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]

				S. A. Ahrendt, Y. Hu, M. Buta, M. P. McDermott, N. Benoit, S. C. Yang, L. Wu, and D. Sidransky p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study J Natl Cancer Inst, July 2, 2003; 95(13): 961 - 970. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				G. Bepler, A. Gautam, L. M. McIntyre, A. F. Beck, D. S. Chervinsky, Y.-C. Kim, D. M. Pitterle, and A. Hyland Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1353 - 1360. [Abstract] [Full Text] [PDF]

				N. Ramnath, F. J. Hernandez, D.-F. Tan, J. A. Huberman, N. Natarajan, A. F. Beck, A. Hyland, I. T. Todorov, J. S.J. Brooks, and G. Bepler MCM2 Is an Independent Predictor of Survival in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., November 15, 2001; 19(22): 4259 - 4266. [Abstract] [Full Text]